OGEN · Oragenics Inc
$0.53
+0.01 (+1.90%)
At close · Aug 26
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Considering our recurring losses, accumulated deficit, and negative cash flows, the report of our independent registered public accounting firm on our consolidated financial statements for the year ended December 31, 2025, included an explanatory paragraph raising substantial doubt about our ability to continue as a going concern. ... These factors raise substantial doubt regarding our ability to continue as a going concern. We plan to pursue additional financing to mitigate liquidity risk; however, substantial doubt about our ability to continue as a going concern remains unless and until we obtain sufficient capital to fund operations beyond the current planning horizon. ... Based on these factors, there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$2.37M
Shares
4.51M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.53
Open$0.54
Day$0.52–0.54
52W close$0.49–1.42
Avg vol 30d29K
Short int789K · 17.5% float · 39.1d
Short vol49%
DataJun 2025–Aug 2026
Filing10-Q · Aug 13
Raw chart and full-history price indicators begin at the captured split on Jun 3, 2025; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−25%
below
Price vs 50-day avg
−4%
below
RSI (14)
47
neutral
MACD trend
Positive
52-week position
4%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+7%
trailing
6-month return
−40%
trailing
YTD return
−32%
this year
Relative strength
−53%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-18% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
17.49% of float · ▲ +1.0% MoM · 39.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
18 holders — mid 3-yr range
Squeeze score
79
high risk · 0–100
Fundamentals
Revenue growth
−9%
Y/Y
Gross margin
0%
EPS growth
+90%
Y/Y
Free cash flow
$-9.4M
Balance sheet
$4.1M
net cash
Quant / Vol
risk profile
Volatility
70%
annualized · 1-yr
Max drawdown
−65%
past year
ATR
5.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−25%
Bearish
Price vs 50-day avg
−4%
Neutral
RSI (14)
47
Neutral
MACD trend
Positive
Bullish
52-week position
4%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-18% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
17.49% of float · ▲ +1.0% MoM · 39.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
18 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $1 · 4%
Range high $1
vs 200-day avg -25%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OGEN
this stock
Oragenics Inc
|
$2.37M | -32.1% | -8.9% | — | 17.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.79B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
Raw-price comparisons begin at the captured split on Jun 3, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OGEN | 0.0% | +6.7% | -40.5% | +6.0% | -32.1% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +0.4% | +1.7% | -52.9% | +3.5% | -44.4% |
Key facts
CIK
1174940
CUSIP
684023609
13F (30d)
17 filings
15 filers
Visit website
Investor relations